Design and Synthesis of New Thiazole Derivatives for Alzheimer’s Disease Therapy as a Potential Cholinesterase Inhibitor; Toxicity Prediction and Molecular Docking Studies and Biological Evaluation
Molecules · 2026
DOI: 10.3390/molecules31193568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Mesut Işık und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Thiazoles, Alzheimer Disease, Drug Design. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu University.
Themen: Demenz
Abstract (Originalsprache)
In this study, thiazole derivatives 13–23 were synthesized as novel cholinesterase inhibitors. Their structures were elucidated using 1H-NMR, 13C-NMR, and elemental analysis techniques. The binding positions and efficiencies of the designed compounds on the enzyme were investigated through molecular docking studies, and the properties of ADMET were examined using computational methods. Cytotoxicity analyses of the synthesized compounds were performed to screen their inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in vitro. It has been determined that these compounds do not exhibit a significant cytotoxic effect on healthy endothelial cells. Although the compounds showed lower efficacy in AChE inhibition compared to the reference compound tacrine (IC50: 0.136 μM; KI: 0.46 ± 0.01 nM), they exhibited moderate inhibitory effects. Among these, compounds 16 and 23 were found to be the most potent AChE inhibitors, with IC50 values of 36.47 µM and 34.65 µM, and KI values of 22.20 ± 1.23 and 21.10 ± 1.58 µM, respectively, while compounds 15 and 20 were found to be the most potent BChE inhibitors, with IC50 values of 17.76 µM and 16.90 µM, and KI values of 14.10 ± 0.58 and 13.40 ± 0.48 µM, respectively, on other cholinesterases. These tested compounds can be considered potential candidates for further research in the treatment of Alzheimer’s disease (AD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.
- Faculty of Pharmacy, University for Business and Technology, 60000 Prishtina, Kosovo.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, 67600 Zonguldak, Turkey.
- Department of Pharmaceutical Chemistry, Graduate School, Anadolu University, 26470 Eskisehir, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan.
ORCID-Profile: Mesut Işık, Gresa Halimi Syla, Yusuf Özkay, Zafer Asım Kaplancıklı
Förderung
- Anadolu University
Zitieren
APA
Işık, M., Syla, G. H., Karakaya, A., Çevik, U. A., Daoud, N. E., Fırat, M., Öğünç Keçeci, Y., Özkay, Y., Kaplancıklı, Z. A., & Beydemir, Ş. (2026). Design and Synthesis of New Thiazole Derivatives for Alzheimer’s Disease Therapy as a Potential Cholinesterase Inhibitor; Toxicity Prediction and Molecular Docking Studies and Biological Evaluation. Molecules. https://doi.org/10.3390/molecules31193568
Vancouver
Işık M, Syla GH, Karakaya A, Çevik UA, Daoud NE, Fırat M, et al. Design and Synthesis of New Thiazole Derivatives for Alzheimer’s Disease Therapy as a Potential Cholinesterase Inhibitor; Toxicity Prediction and Molecular Docking Studies and Biological Evaluation. Molecules. 2026. doi:10.3390/molecules31193568
BibTeX
@article{Ik2026,
author = {Işık, Mesut and Syla, Gresa Halimi and Karakaya, Abdüllatif and Çevik, Ulviye Acar and Daoud, Nour El-Huda and Fırat, Muhammet and Öğünç Keçeci, Yüksel and Özkay, Yusuf and Kaplancıklı, Zafer Asım and Beydemir, Şükrü},
title = {Design and Synthesis of New Thiazole Derivatives for Alzheimer’s Disease Therapy as a Potential Cholinesterase Inhibitor; Toxicity Prediction and Molecular Docking Studies and Biological Evaluation},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31193568}
}
EUVIMED